Rein therapeutics announces a publication in biomedicines on the immunomodulatory and anti-fibrotic properties of a caveolin-1-related peptide in ipf and pasc-f

Manuscript highlights the effects of caveolin scaffolding domain peptide lti-2355 on myeloid cell activity in idiopathic pulmonary fibrosis (ipf) and post-acute sequelae of covid fibrosis (pasc-f) austin, texas , april 15, 2025 /prnewswire/ -- rein therapeutics ("rein") (nasdaq: rntx), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced a publication highlighting the therapeutic potential of caveolin-1-related peptide lti-2355 in idiopathic pulmonary fibrosis (ipf) and post-acute sequelae of covid fibrosis (pasc-f) in the peer-reviewed journal, biomedicines. the manuscript, titled "caveolin scaffolding domain (csd) peptide lti-2355 modulates the phagocytic and synthetic activity of lung-derived myeloid cells in idiopathic pulmonary fibrosis (ipf) and post-acute sequelae of covid fibrosis (pasc-f)," describes the effects of caveolin scaffolding domain (csd) peptide lti-2355 on the immune and synthetic properties of human lung-derived macrophages and other myeloid cells isolated from lung explant tissue of donor lungs, as well as ipf and pasc-f lung explant tissue.
RNTX Ratings Summary
RNTX Quant Ranking